{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for penicillin root_references_citation in Reference Text / Citation (approximate match)
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Cimicifuga U.S.P.
(1921)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02054455: Phase 4 Interventional Completed Gastrointestinal Symptoms
(2012)
Source URL:
First approved in 2020
Source:
BACICAP PROBIOTIC by NATIONAL BIO GREEN SCIENCES LIMITED LIABILTY COMPANY
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03472014: Phase 4 Interventional Completed Vaccination
(2010)
Source URL:
First approved in 2019
Source:
BLA125678
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2004
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(1991)
Source URL:
First approved in 1991
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04675359: Phase 4 Interventional Unknown status Knee Osteoarthritis
(2021)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
